Home > Press > QBI Life Sciences uses Nanotechnology to advance Drug Discovery
QBI Life Sciences uses Nanotechnology to advance Drug Discovery
Madison, WI | August 10, 2005
Long interested in advancing the process of discovering new treatments for human diseases, the principals of QBI Life Sciences today announced the release of a second polymeric micelle product, PreserveX™-QML-B Polymeric Micelles. PreserveX™ Polymeric Micelles, useful in working with difficult to handle proteins average 21 nanometers in diameter. In the presence of native cell membrane fractions, PreserveX™ Polymeric Micelles self-assemble embedding pieces of cellular membranes in the complex creating multiple particles each providing an environment similar to that of the native membrane. Below is an illustration of this process.
The newly released product, PreserveX™-QML-B Polymeric Micelles contains a biotin label enabling the placement of the micelle/protein/lipid complex onto a solid support such as a protein microarray. Below is an illustration of complexes immobilized on a solid support.
PreserveX™ Polymeric Micelles reflect the combination of polymer chemistry technologies with protein chemistry technologies. Vladimir Trubetskoy, Ph.D., Director of Polymer Chemistry has headed up a team at QBI Life Sciences to develop polymer nano-particles that are useful in working with some of the most difficult to handle proteins. Focusing on membrane proteins (those proteins that reside on, near or embedded in cellular membranes), Dr. Trubetskoy and his team of scientists have come up with a set of very valuable drug discovery tools. In the area of human health, membrane proteins represent 70% of all known drug targets, the agents inside the human body upon which drugs evoke a therapeutic effect. To date, efforts to study these proteins and develop drugs targeting these proteins have been limited.
Announcement of the introduction of PreserveX™-QML-B is coincident with a presentation of product performance at the 2005 Drug Discovery Technology® & Development World Congress in Boston, Massachusetts (link).
About QBI Life Sciences:
QBI Life Sciences is a division of Quintessence Biosciences, Inc. QBI Life Sciences is focused on development and supply of research tools focused on work with membrane proteins. The aim of the Company’s product development efforts is to enable new areas of research.
For more information, please visit www.qbilifesci.com
Media Contact:Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
Self Assembly
Diamond glitter: A play of colors with artificial DNA crystals May 17th, 2024
Liquid crystal templated chiral nanomaterials October 14th, 2022
Nanoclusters self-organize into centimeter-scale hierarchical assemblies April 22nd, 2022
Atom by atom: building precise smaller nanoparticles with templates March 4th, 2022
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||